BioSpace News Archive

The White House announced today that the US has shipped 400 million doses of COVID-19 vaccines around the world, a milestone that AIDS Healthcare Foundation (AHF) described as commendable but still far short of what is needed to vaccinate our world.

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB).

Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in the Company’s prostate-specific membrane antigen (PSMA) targeting ‘ProstACT’ therapeutic program, which is exploring TLX591 in areas of unmet medical need across the full prostate cancer treatment journey.

Trial lawyers with the Lanier Law Firm have filed a $10 million lawsuit against Johnson & Johnson, its Janssen Pharmaceuticals subsidiary, and other parties on behalf of a New Hampshire woman who suffered eye damage after long-term use of the drug Elmiron, prescribed for bladder pain

IQVIA (NYSE:IQV) today announced the appointment of Sheila A. Stamps to its board of directors, effective today.

Moderna, Inc., a biotechnology company pioneering messenger RNA therapeutics and vaccines, announced that the first participant has been dosed in the Phase 2 study of the Company’s Omicron-specific booster candidate.

SQI Diagnostics Inc. (‘SQI” or the “Company”) (TSXV: SQD) (OTCQB: SQIDF), today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2021.

Galvani Bioelectronics, today announced that the first patient with Rheumatoid Arthritis (RA) has been treated through stimulation of the splenic nerve using its novel bioelectronics platform.

Leonhardt Ventures LLC, a Mission Viejo, California based company via it’s innovation and startup launch accelerator Leonhardt’s Launchpads, announced today that it has begun an active research program to combine its patent-pending klotho expression bioelectric stimulation technologies with newly acquired klotho expressing mesenchymal stem cell technology.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, announced that an IND application to initiate the first clinical trial in China for 3D189, also known as SELLAS’ galinpepimut-S, has been accepted by China’s National Medical Products Administration.